GENINUS Inc. (KOSDAQ:389030)
4,090.00
+295.00 (7.77%)
At close: Jan 27, 2026
GENINUS Company Description
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia.
It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform.
It serves hospitals, pharmaceutical companies, and researchers. The company was founded in 2018 and is headquartered in Seoul, South Korea.
GENINUS Inc.
| Country | South Korea |
| Founded | 2018 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| CEO | Woongyang Park |
Contact Details
Address: KDU Tower Seoul, 05836 South Korea | |
| Phone | 82 2 6949 6580 |
| Website | kr-geninus.com |
Stock Details
| Ticker Symbol | 389030 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Woongyang Park | Chief Executive Officer |
| Wansung Ku | Chief Financial Officer |
| Yongju Bang | Chief Operating Officer |